Illumina (NASDAQ:ILMN) Updates FY 2021 Earnings Guidance

Illumina (NASDAQ:ILMN) issued an update on its FY 2021 earnings guidance on Thursday morning. The company provided earnings per share guidance of $5.500-$5.600 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.730. The company issued revenue guidance of $4.41 billion-$4.41 billion, compared to the consensus revenue estimate of $4.35 billion.

Illumina stock traded down $0.18 during trading on Thursday, reaching $365.56. The company had a trading volume of 1,112,567 shares, compared to its average volume of 895,605. The firm’s 50-day simple moving average is $405.93 and its 200 day simple moving average is $439.86. Illumina has a 1-year low of $301.73 and a 1-year high of $555.77. The firm has a market capitalization of $57.14 billion, a PE ratio of 60.03, a price-to-earnings-growth ratio of 2.17 and a beta of 0.87. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.24 and a current ratio of 2.68.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, November 4th. The life sciences company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.24 by $0.21. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.04 billion. Illumina had a return on equity of 15.03% and a net margin of 21.17%. The firm’s revenue for the quarter was up 39.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.02 EPS. Analysts anticipate that Illumina will post 5.61 EPS for the current year.

A number of research analysts have weighed in on the company. Barclays raised their price objective on Illumina from $355.00 to $365.00 and gave the company an underweight rating in a report on Friday, August 6th. Robert W. Baird decreased their price objective on Illumina from $493.00 to $437.00 and set a neutral rating on the stock in a report on Monday, November 8th. TheStreet lowered Illumina from a b- rating to a c rating in a report on Wednesday, October 6th. Zacks Investment Research lowered Illumina from a hold rating to a strong sell rating and set a $390.00 price objective on the stock. in a report on Tuesday, October 19th. Finally, SVB Leerink reduced their price target on Illumina from $425.00 to $420.00 and set a market perform rating on the stock in a report on Tuesday, October 19th. Three research analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Hold and an average price target of $424.00.

In related news, SVP Susan H. Tousi sold 300 shares of the business’s stock in a transaction dated Monday, August 30th. The shares were sold at an average price of $463.50, for a total value of $139,050.00. Following the sale, the senior vice president now directly owns 41,456 shares in the company, valued at approximately $19,214,856. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Charles Dadswell sold 314 shares of Illumina stock in a transaction dated Monday, November 22nd. The shares were sold at an average price of $377.86, for a total value of $118,648.04. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,507 shares of company stock worth $6,001,240. Insiders own 0.23% of the company’s stock.

Illumina Company Profile

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions.

Recommended Story: Float

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with's FREE daily email newsletter.